Abstracts

4th Generation Rapid Tests Improve Detection of Acute Infection in MTN-003 (VOICE)

The greatest risk of antiretroviral resistance from pre-exposure prophylaxis is conferred by use during undetected acute infection. Early, accurate identification of infection in HIV prevention trials is critical for protection of human subjects, data quality and study efficiency. We evaluated pre-seroconversion plasma from the VOICE Study (MTN-003) to determine if 4th generation antigen/antibody (Ag/Ab) rapid…

HIV Testing in the US PrEP Demonstration Project: rEIA vs Antigen/Antibody vs RNA

Ensuring individuals are HIV-uninfected prior to pre-exposure prophylaxis (PrEP) initiation and continuation is critical to minimize the risk of developing resistance, but the optimal HIV testing algorithm for PrEP is not yet known. We evaluated the performance of rapid blood EIA (rEIA), lab-based p24-antigen/antibody (4th generation), and RNA tests in detecting HIV infection at PrEP…

Early Mortality Risk of HIV/Hepatitis B Virus Coinfected Patients Initiating ART

Hepatitis B virus (HBV) co-infection, common in HIV-infected patients in sub-Saharan Africa, is associated with impaired immunological recovery while on antiretroviral treatment (ART), and worse clinical outcomes, even in the context of effective ART.  A clear association between HBV co-infection and early mortality has not been shown in African settings and the impact of tenofovir-containing…

Long-Term Changes in Liver Fibrosis in HIV and HIV/HBV Infected Nigerians on ART

There are limited longitudinal data on changes in liver fibrosis by transient elastography (TE) in HIV/HBV co-infected patients on HBV active antiretroviral therapy (ART) in sub-Saharan Africa. Correlations with HBV DNA levels have also not been performed. This is a prospective analysis of ART-naïve, HIV and HIV/HBV co-infected adults (>18) at Jos University Teaching Hospital…

Tenofovir and the Incidence of Hepatocellular Carcinoma in HIV/HBV-Coinfected Persons

Hepatocellular carcinoma (HCC) is a leading cause of death in HIV/hepatitis B virus (HBV)-coinfected patients. Current screening recommendations are based on incidence estimates in untreated HBV-infected patients and might be inadequate for HIV/HBV-coinfected individuals on antiretroviral therapy (ART). We explored the impact of tenofovir (TDF) on HCC incidence in a large collaboration of HIV cohorts…